Misted chemotherapy shows promise for Hard-to-Treat abdominal cancers

NCT ID NCT07271355

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests a new method called PIPAC that delivers chemotherapy as a pressurized mist directly into the abdomen during a minimally invasive procedure. It compares this approach plus standard intravenous chemo (FOLFIRI) to standard chemo alone for people with appendix or colorectal cancer that has spread to the lining of the abdomen and cannot be removed by surgery. The study aims to see if the combination helps people live longer. About 129 adults with good performance status will participate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for APPENDICEAL CANCER WITH PERITONEAL METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CTCA at Western Regional Medical Center

    Goodyear, Arizona, 85338, United States

  • City of Hope Atlanta Cancer Center

    Newnan, Georgia, 30265, United States

  • City of Hope Comprehensive Cancer Center

    Duarte, California, 91010, United States

  • City of Hope at Chicago

    Zion, Illinois, 60099, United States

  • City of Hope at Irvine Lennar

    Irvine, California, 92618, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.